Compare Boston Scientific Corporation (BSX) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs KeyCorp — how do they compare? Boston Scientific Corporation trades at $50.53 (market cap $74.19B), while KeyCorp trades at $22.69 (market cap $24.32B). The key difference: Boston Scientific Corporation is far larger — about 3.1× KeyCorp's market cap, and KeyCorp pays a 3.61% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | KEY | |
|---|---|---|
Market Cap | $74.19B | $24.32B |
Sector | Health | Financials |
52-Week High | $108.14 | $23.99 |
52-Week Low | $42.63 | $16.78 |
Enterprise Value | $86.27B | — |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
KeyCorp (KEY) trades at $22.68, down 0.22% on the day, with a bearish technical signal but strong fundamental recovery. The company reported Q2 2026 EPS of $0.44, beating estimates, and shows robust revenue growth to $7.29B in 2025. Recent expansion includes the acquisition of Clearwater UK, enhancing its investment banking footprint.
The outlook is positive with a consensus price target of $29.41, representing significant upside. Risks include economic uncertainty impacting loan growth and net interest income. The stock offers a dividend yield supported by consistent payouts, with analyst sentiment strongly favoring a buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
